Uniqure N.V.

Novo Nordisk bid upends Pfizer’s plans for smooth takeout of standout U.S. obesity play

Biotech’s value halved on Monday after agency reverses course on Huntington’s therapy; move drags down other biotechs 

Plus: More follow-ons for Immuneering, PepGen and Monopar; MapLight seeking a NASDAQ listing; and more

Plus: MBX shares rise on data from long-acting hormone replacement therapy, and more

Also in BioCentury’s clinical report, heparan sulfate gets more clinical validation in MPS, but will the biomarker ever be a surrogate endpoint?

New Year to put new obesity targets to the test, as all eyes on semaglutide in Alzheimer’s and launches in schizophrenia, AMD

BioCentury’s analysts look back at a year when innovation was hot, but markets were not, and predict what’ll make news in 2025

Biotech retains upside in licensing agreement for oral therapy derived from same splicing platform as SMA drug

Plus: Seaport hires Lauren White as CFO, and updates from Tarsus and Takeda

FDA will accept Phase I/II data on Fabry gene therapy, obviating need for Phase III trial